READING, PA — SAI MedPartners has acquired The Dunn Group, strengthening its competitive intelligence capabilities as demand rises for deeper insight into crowded pharmaceutical and biotechnology pipelines.
The Dunn Group, headquartered in Totowa, New Jersey, specializes in primary business intelligence for life sciences companies, helping clients assess competitive landscapes by analyzing drug pipelines, monitoring therapy areas, and conducting analogue assessments. Financial terms of the transaction were not disclosed.
SAI said the acquisition enhances its core competitive intelligence offering, adding depth to its ability to support pharmaceutical and biotech clients navigating increasingly complex development and commercialization decisions.
SAI has been backed by Northlane Capital Partners since June 2022, when the private equity firm partnered with management to acquire the company. Since then, SAI has focused on expanding its service portfolio and strengthening its position as a strategic partner to life sciences organizations.
Founder and Chief Executive Officer Erik Nordhoy said the Dunn Group brings a long-established reputation in healthcare intelligence and complements SAI’s existing platform. He said the addition is expected to deepen client relationships and reinforce SAI’s ability to deliver high-value insights across the product life cycle.
The transaction reflects broader consolidation across the life sciences services sector, as companies seek scale, specialized expertise, and differentiated data capabilities to support pharmaceutical clients facing heightened competition, regulatory scrutiny, and pressure to accelerate development timelines.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.